FDA approves new type of drug for insomnia
On August 13, the U.S. Food and Drug Administration (FDA) approved Belsomra (suvorexant) tablets for treating insomnia. Belsomra is the first approved orexin receptor…
News
FDA approves new drug for type 2 diabetes
On August 1, the U.S. Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic…
FDA approves new drug for skin infections
On August 6, the U.S. Food and Drug Administration (FDA) approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections. Read…
FDA approves Afrezza
On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control…
FDA approves drug for treating rare type of non-Hodgkin lymphoma
On July 3, the U.S. Food and Drug Administration (FDA) approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma, a rare…
FDA approves new product to treat hereditary angioedema
On July 16, the U.S. Food and Drug Administration (FDA) approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks…
FDA launches new website for accessing health databases
On June 2, the U.S. Food and Drug Administration (FDA) launched openFDA, a new initiative designed to make it easier for web developers, researchers,…
FDA approves new indication for imaging agent
On June 13, the U.S. Food and Drug Administration (FDA) a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent…
FDA approves new drug for serious skin infections
On June 20, the U.S. Food and Drug Administration (FDA) approved Sivextro (tedizolid phosphate) to treat patients with acute bacterial skin and skin structure…
FDA approves Zykadia for NSCLC
On April 29, the U.S. Food and Drug Administration (FDA) approved Zykadia for patients with a certain type of late-stage non-small cell lung cancer…
FDA approves new type of drug for insomnia
On August 13, the U.S. Food and Drug Administration (FDA) approved Belsomra (suvorexant) tablets for treating insomnia. Belsomra is the first approved…
FDA approves new drug for type 2 diabetes
On August 1, the U.S. Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to…
FDA approves new drug for skin infections
On August 6, the U.S. Food and Drug Administration (FDA) approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin…
FDA approves Afrezza
On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve…
FDA approves drug for treating rare type of non-Hodgkin lymphoma
On July 3, the U.S. Food and Drug Administration (FDA) approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma,…
FDA approves new product to treat hereditary angioedema
On July 16, the U.S. Food and Drug Administration (FDA) approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of…
FDA launches new website for accessing health databases
On June 2, the U.S. Food and Drug Administration (FDA) launched openFDA, a new initiative designed to make it easier for web…
FDA approves new indication for imaging agent
On June 13, the U.S. Food and Drug Administration (FDA) a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic…
FDA approves new drug for serious skin infections
On June 20, the U.S. Food and Drug Administration (FDA) approved Sivextro (tedizolid phosphate) to treat patients with acute bacterial skin and…
FDA approves Zykadia for NSCLC
On April 29, the U.S. Food and Drug Administration (FDA) approved Zykadia for patients with a certain type of late-stage non-small cell…
Test Your Knowledge
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.